|
Lives saved, including ‘statistical’ lives (i.e. cure or reduced risk of death)
| |
|
None (or not yet known)
|
0
|
|
Few: 1-50 lives saved
|
0.091
|
|
Some: 51-250 lives saved
|
0.192
|
|
Many: 251-500 lives saved
|
0.268
|
|
Very many: > 500 lives saved
|
0.343
|
|
Life-prolongation benefits – in terms of increase in life expectancy and its quality-of-life, and number of patients affected
| |
|
None/Very small (or not yet known)
|
0
|
|
Small benefits
|
0.053
|
|
Medium benefits
|
0.152
|
|
Large benefits
|
0.244
|
|
Quality-of-life gains – in terms of baseline QoL, size of QoL gains and duration, and number of patients affected
| |
|
None/Very small (or not yet known)
|
0
|
|
Small QoL gains
|
0.051
|
|
Medium QoL gains
|
0.138
|
|
Large QoL gains
|
0.217
|
|
If this technology were
not
to be funded …
| |
|
Many/most patients will be able to pay for it themselves (privately)
|
0
|
|
Many/most patients will get an alternative treatment (less effective) already funded by government
|
0.055
|
|
Many/most patients will not receive any treatment for condition
|
0.108
|
|
Other important social or ethical benefits, e.g. targeted to children/minorities; reduces health gaps, etc
| |
|
None/Very small (or not yet known)
|
0
|
|
Yes
|
0.087
|
